Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder

BackgroundEpstein–Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2021-07, Vol.11
Main Authors: Yan, Nan, Wang, Na, Zhang, Peiling, Wang, Gaoxiang, Mao, Xia, Peng, Dan, Kuang, Dong, Chen, Liting, Zhu, Li, Zhou, Jianfeng, Zhang, Yicheng, Cao, Yang
Format: Article
Language:English
Subjects:
ALL
CAR-T
EBV
HSCT
Oncology
PTLD
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundEpstein–Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation and PTLD. However, reports on the curative management of refractory PTLD are scarce.Case PresentationIn this report, we describe the successful management of two patients with EBV-PTLD with chimeric antigen receptor T-cell (CAR-T) therapy.ConclusionThe present results demonstrated that patients with EBV-PTLD may benefit from CAR-T therapy and that the toxicity is manageable. Further studies are needed to verify these findings.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.709370